In addition to targeted tumor specific Treg depletion via CTLA-4 blockade, other pharmacologic targets have been demonstrated to yield improved degrees of tumor rejection and restoration of the anti-tumor immune response. The gene discussed is CTLA4; the disease is neoplasm.